Tag: source

Please see below information about transactions made under the second tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2025.

AB „Ignitis grupė“ (toliau – Grupė) informuoja, kad birželio 30 d., gavus Grupės valdybos patvirtinimą, Grupės dukterinės įmonės UAB „Ignitis renewables“ (toliau – „Ignitis renewables“) ir AB „Ignitis gamyba“ (toliau – „Ignitis gamyba“) priėmė galutinius investicinius sprendimus dėl trijų elektros energijos kaupiklių sistemų (toliau – EEKS) projektų Lietuvoje, kurių bendra galia siekia 291 MW, o talpa – 582 MWh. Vokietijos bendrovė Rolls-Royce Solutions GmbH yra pasirinkta dėl įrangos tiekimo ir jos integravimo visiems trims projektams.

AB “Ignitis grupė” (hereinafter – the Group) informs that on 30 June, with the agreement of the Group’s Management Board, the Group’s subsidiaries UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) and AB “Ignitis gamyba” (hereinafter – Ignitis Gamyba) made final investment decisions on three battery energy storage system (hereinafter – BESS) projects in Lithuania, with a combined 291 MW power and 582 MWh storage capacity. The German company Rolls-Royce Solutions GmbH will provide the equipment and the integration services for all three BESS projects.

PRESS RELEASE

Amsterdam, July 1, 2025

AB “Ignitis grupė” (hereinafter – the Group) informs that on 30 June, with the agreement of the Group’s Management Board, the Group’s subsidiaries UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) and AB “Ignitis gamyba” (hereinafter – Ignitis Gamyba) made final investment decisions on three battery energy storage system (hereinafter – BESS) projects in Lithuania, with a combined 291 MW power and 582 MWh storage capacity. The German company Rolls-Royce Solutions GmbH will provide the equipment and the integration services for all three BESS projects.

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.